Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/27/16 → 7/10/20 |
Funding
- Stemcentrx Incorporated: $382,524.00
16-MULTI-15-SI: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with for Delta-Like Protein-Expressing Advanced Solid Tumors
- Anthony, Lowell (PI)
- Arnold, Susanne (CoI)
- Villano, PhD, John (CoI)
- Wang, Peng (CoI)